In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities

Molecular Cancer Therapeutics

Volumn 7, Issue 12, 2008, Pages 3878-3888

  Bisht, Savita ^a   Feldmann, Georg ^a   Koorstra, Jan Bart M ^a,c   Mullendore, Michael ^a   Alvarez, Hector ^a   Karikari, Collins ^a   Rudek, Michelle A ^a   Lee, Carlton K ^a   Maitra, Amarnath ^b   Maitra, Anirban ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DELHI   (India)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID; METHACRYLIC ACID METHYL ESTER; NANOPARTICLE; NMA 622; NVA 622; POLY(N ISOPROPYLACRYLAMIDE); RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; KINETICS; MICE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; POLYMERS; SIROLIMUS; TECHNOLOGY, PHARMACEUTICAL;

EID: 57749108568     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0476     Document Type: Article

References (48)

1. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004;58:265-78.
2. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003;24:253-62.
3. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85.
4. Heath JR, Davis ME. Nanotechnology and cancer. Annu Rev Med 2008;59:251-65.
5. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-9.
6. Borner MM, Schoffski P, de Wit R, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002;38:349-58.
7. Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008;19:212-22.
8. Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. Br J Cancer 2006;95:27-34.
9. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-46.
10. Averous J, Proud CG. When translation meets transformation: the mTOR story. Oncogene 2006;25:6423-35.
11. Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008;62:305-13.
12. Settleman J, Kurie JM. Drugging the bad "AKT-TOR" to overcome TKI-resistant lung cancer. Cancer Cell 2007;12:6-8.
13. Napoli KL, Wang ME, Stepkowski SM, Kahan BD. Distribution of sirolimus in rat tissue. Clin Biochem 1997;30:135-42.
14. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-61.
15. Rubio-Viqueira B, Mezzadra H, Nielsen ME, et al. Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. Mol Cancer Ther 2007;6:515-23.
16. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007;130:1120-33.
17. Vicente FB, Smith FA, Peng Y, Wang S. Evaluation of an immunoassay of whole blood sirolimus in pediatric transplant patients in comparison with high-performance liquid chromatography/tandem mass spectrometry. Clin Chem Lab Med 2006;44:497-9.
18. Wang S, Magill JE, Vicente FB. A fast and simple high-performance liquid chromatography/mass spectrometry method for simultaneous measurement of whole blood tacrolimus and sirolimus. Arch Pathol Lab Med 2005;129:661-5.
19. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-96.
20. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19:6680-6.
21. Ruvinsky I, Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 2006;31:342-8.
22. Langer R. Drug delivery and targeting. Nature 1998;392:5-10.
23. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert review of anticancer therapy 2007;7:919-43.
24. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006;16:175-83.
25. Alberts DS, Muggia FM, Carmichael J, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004;31:53-90.
26. Kim DW, Kim SY, Kim HK, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:2009-14.
27. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Deliv Rev 2008;60:899-914.
28. Boddy AV, Plummer ER, Todd R, et al. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin Cancer Res 2005;11:7834-40.
29. Nahar M, Dutta T, Murugesan S, et al. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit Rev Ther Drug Carrier Systems 2006;23:259-318.
30. Pridgen EM, Langer R, Farokhzad OC. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomed 2007;2:669-80.
31. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnol 2007;5:3.
32. Damge C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 2008;5:45-68.
33. Bhavsar MD, Amiji MM. Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin Drug Deliv 2007;4:197-213.
34. Yoncheva K, Gomez S, Campanero MA, Gamazo C, Irache JM. Bioadhesive properties of pegylated nanoparticles. Expert Opin Drug Deliv 2005;2:205-18.
35. Ma WW, Jimeno A. Temsirolimus. Drugs Today (Barc) 2007;43:659-69.
36. Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 2006;7:501-12.
37. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006;17:487-94.
38. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26:361-7.
39. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004;113:151-70.
40. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006;24:1211-7.
41. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876-85.
42. Hoet PH, Bruske-Hohlfeld I, Salata OV. Nanoparticles - known and unknown health risks. J Nanobiotechnol 2004;2:12.
43. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457-64.
44. MacDiarmid JA, Madrid-Weiss J, Amaro-Mugridge NB, Phillips L, Brahmbhatt H. Bacterially-derived nanocells for tumor-targeted delivery of chemotherapeutics and cell cycle inhibitors. Cell Cycle Georgetown TX 2007;6:2099-105.
45. MacDiarmid JA, Mugridge NB, Weiss JC, et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 2007;11:431-45.
46. Maitra A, Hruban RH. Pancreatic cancer. Annual review of pathology 2008;3:157-88.
47. Foss CA, Fox JJ, Feldmann G, et al. Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. Mol Imaging 2007;6:131-9.
48. Qian J, Yong KT, Roy I, et al. Imaging pancreatic cancer using surface-functionalized quantum dots. J Phys Chem 2007;111:6969-72.